Kriya Therapeutics Secures $313 Million in Major Gene Therapy Funding Round

Gene therapy biotech Kriya Therapeutics has raised $313 million in a new series financing round, marking one of the largest private biotech fundraises of the year. The equity financing, disclosed in a Securities and Exchange Commission filing on August 15, 2025, solidifies Kriya's position as a frontrunner in the gene therapy space and signals renewed investor confidence in the field.

Financing Details and Industry Context

The $313 million raise places Kriya's latest round among the top biotech financings of 2025, surpassed only by Verdiva Bio's $410 million launch, MapLight Therapeutics' $372 million series D, and Eikon Therapeutics' $350 million series D. This substantial investment comes at a crucial time for the gene therapy sector, which has faced waning investor enthusiasm over the past year.

Kriya's fundraising success follows its impressive 2022 series C round, which initially brought in $270 million and was later extended by an additional $150 million in July 2023, totaling $430 million. The company's ability to secure significant funding in the current climate underscores the potential of its gene therapy platform and pipeline.

Kriya's Pipeline and Strategic Acquisitions

Kriya Therapeutics boasts a diverse pipeline of nine programs spanning neurology, metabolic health, and ophthalmology. Two of these assets have already entered clinical development, according to the company's website. The biotech has strategically expanded its portfolio through acquisitions, including the purchase of Redpin Therapeutics and Tramontane Therapeutics in 2022 and 2023, respectively.

The Redpin acquisition bolstered Kriya's neurology candidates, adding programs for epilepsy and trigeminal neuralgia. Meanwhile, the Tramontane deal brought in a metabolic dysfunction-associated steatohepatitis program, further diversifying Kriya's therapeutic reach.

Leadership Vision and Industry Impact

Shankar Ramaswamy, M.D., Kriya's co-founder and CEO, emphasized the company's ambitious goals in a 2023 fundraising release: "We have an ambitious goal to advance gene therapies to highly prevalent diseases that affect millions of people around the world." Ramaswamy, brother of Roivant Sciences founder and aspiring politician Vivek Ramaswamy, further stated, "In order to make gene therapies a cornerstone of mainstream medicine, we have built a fully integrated engine to overcome industry-wide challenges that have constrained research, development and manufacturing in the field of gene therapy."

Kriya's substantial funding round and expanding pipeline position the company as a key player in the evolving gene therapy landscape. As the biotech continues to advance its programs and integrate its strategic acquisitions, industry observers will be watching closely to see how Kriya's approach may reshape the future of gene therapy development and commercialization.